Results for the First Quarter 2026

Medistim Passes MNOK 200 in Quarterly Sales for the FirstTime

Medistim achieved a historic milestone in the first quarter of 2026, with total sales exceeding MNOK 200 for the very first time. Revenue reached MNOK 201.7, up 11.1% from the same quarter last year.

Currency-neutral growth of own products was strong at 28.8%,driven by solid performance across all geographies. APAC led the way with 57.5%growth, followed by AMERICAS at 30.9% and EMEA at 11.5%. Third-partydistributor sales in Scandinavia decreased by 30.2%, reflecting anexceptionally strong comparable from Q1 2025.

Operating profit (EBIT) came in at MNOK 57.1, correspondingto an EBIT margin of 28.3%. Recurring sales remained high at 67.8%, and thecompany ended the quarter with a solid cash position of MNOK 209.8 and nointerest-bearing bank loans.

A significant strategic development in the quarter was theestablishment of Medistim's direct sales operation in Japan, effective March16, 2026 — reinforcing the company's commitment to long-term growth in theAsia-Pacific region.

The General Assembly approved a dividend of NOK 8.00 pershare, totaling MNOK 146.2.

Read the full quarterly report and presentation here: Medistim First Quarter